A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer (NCT06638307)

🧪 Interventions in This Study

• MEN2312 (DRUG)
• Elacestrant (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (45 Sites)

Showing the first 25 of 45 sites.

• Highlands Oncology Group — Springdale, Arkansas
• City of Hope — Duarte, California
• UC San Diego Moores Cancer Center — La Jolla, California
• Stanford Cancer Center — Palo Alto, California
• UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
• UCLA Hematology Oncology - Parkside — Santa Monica, California
• Yale Comprehensive Cancer Center — New Haven, Connecticut
• Advent Health Orlando — Altamonte Springs, Florida
• Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando, Florida
• Florida Cancer Specialists & Research Institute (FCS) - Sarasota — Sarasota, Florida
• Moffitt Cancer Center — Tampa, Florida
• Winship Cancer Institute, Emory University — Atlanta, Georgia
• University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center) — Chicago, Illinois
• University of Chicago Medical Center — Chicago, Illinois
• University of Iowa Health Care — Iowa City, Iowa
• The University of Kansas Cancer Center — Fairway, Kansas
• Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
• Massachusetts General Hospital Cancer Center — Boston, Massachusetts
• Dana-Farber Cancer Institute — Boston, Massachusetts
• START Midwest - Oncology — Grand Rapids, Michigan
• Mayo Clinic — Rochester, Minnesota
• Astera Cancer Care — East Brunswick, New Jersey
• Perlmutter Cancer Center - Sunset Park — Brooklyn, New York
• Perlmutter Cancer Center at NYU Langone Hospital - Long Island — Mineola, New York
• Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York

📞 Contact the Study Coordinator

Phone: (877) 332-7961

Email: clinicaltrials@menarinistemline.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Breast Cancer

• RCT of CBD for Anxiety in Advanced Breast Cancer — Boston, Massachusetts
• A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer — Encinitas, California
• Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer — St Louis, Missouri
• Engage Psychosocial Intervention for Cancer Symptoms — Durham, North Carolina
• A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors — Duarte, California

Explore by condition: All Advanced Breast Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.